| Code | CSB-RA021334MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to DS-1103, targeting signal regulatory protein alpha (SIRPα), a critical immune checkpoint receptor expressed on myeloid cells including macrophages and dendritic cells. SIRPα interacts with CD47, a "don't eat me" signal displayed on cell surfaces, to inhibit phagocytosis and regulate innate immune responses. This pathway is frequently exploited by cancer cells that overexpress CD47 to evade immune surveillance, making SIRPα-CD47 interaction a key mechanism of tumor immune evasion. Dysregulation of this axis has been implicated in various malignancies, including hematologic cancers and solid tumors, as well as inflammatory and autoimmune conditions.
DS-1103 is a clinical-stage therapeutic antibody designed to block the SIRPα-CD47 interaction, thereby enhancing macrophage-mediated phagocytosis of tumor cells and promoting anti-tumor immunity. This biosimilar provides researchers with a valuable tool for investigating SIRPα biology, exploring innate immune checkpoint mechanisms, and studying potential therapeutic strategies for cancer immunotherapy. It supports investigations into macrophage function, tumor microenvironment dynamics, and combination immunotherapy approaches.
There are currently no reviews for this product.